Bicocca Open Archive

Logo unimib boa
RIZZARI, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.669
AS - Asia 6.355
EU - Europa 5.129
SA - Sud America 988
Continente sconosciuto - Info sul continente non disponibili 599
AF - Africa 138
OC - Oceania 14
Totale 25.892
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.847
SG - Singapore 2.314
IT - Italia 1.426
VN - Vietnam 1.145
CN - Cina 1.128
HK - Hong Kong 876
RU - Federazione Russa 803
DE - Germania 754
BR - Brasile 734
CA - Canada 581
IE - Irlanda 490
SE - Svezia 487
UA - Ucraina 222
FR - Francia 211
GB - Regno Unito 208
BD - Bangladesh 162
IN - India 154
FI - Finlandia 132
AR - Argentina 87
AT - Austria 79
ID - Indonesia 76
KR - Corea 76
TR - Turchia 64
NL - Olanda 63
MX - Messico 57
IQ - Iraq 56
CO - Colombia 52
PL - Polonia 49
ES - Italia 48
ZA - Sudafrica 47
PH - Filippine 42
PK - Pakistan 39
EC - Ecuador 38
SA - Arabia Saudita 38
JP - Giappone 35
CR - Costa Rica 30
HN - Honduras 29
VE - Venezuela 28
DK - Danimarca 20
JM - Giamaica 20
EG - Egitto 18
UZ - Uzbekistan 18
CZ - Repubblica Ceca 17
MY - Malesia 17
AE - Emirati Arabi Uniti 16
PR - Porto Rico 16
KE - Kenya 15
MA - Marocco 15
BE - Belgio 14
CH - Svizzera 14
CL - Cile 14
GT - Guatemala 14
AU - Australia 13
JO - Giordania 13
LT - Lituania 12
PY - Paraguay 12
IL - Israele 11
NI - Nicaragua 11
SV - El Salvador 11
GR - Grecia 10
TT - Trinidad e Tobago 10
BG - Bulgaria 9
CW - ???statistics.table.value.countryCode.CW??? 9
EE - Estonia 9
PE - Perù 9
RO - Romania 9
TH - Thailandia 9
BO - Bolivia 8
BZ - Belize 8
TN - Tunisia 8
AL - Albania 7
IR - Iran 7
LB - Libano 7
NO - Norvegia 7
DO - Repubblica Dominicana 6
ET - Etiopia 6
GP - Guadalupe 6
KZ - Kazakistan 6
NP - Nepal 6
PA - Panama 6
RS - Serbia 6
CI - Costa d'Avorio 5
DZ - Algeria 5
OM - Oman 5
PT - Portogallo 5
UY - Uruguay 5
AO - Angola 4
AZ - Azerbaigian 4
BB - Barbados 4
BW - Botswana 4
BY - Bielorussia 4
DM - Dominica 4
EU - Europa 4
HR - Croazia 4
BA - Bosnia-Erzegovina 3
BS - Bahamas 3
LK - Sri Lanka 3
LV - Lettonia 3
MN - Mongolia 3
PS - Palestinian Territory 3
Totale 25.261
Salva come PNG Salva come JPEG
Città #
Ashburn 1.333
Ann Arbor 1.254
Singapore 1.233
Hong Kong 856
San Jose 806
Frankfurt am Main 570
Fairfield 484
Woodbridge 480
Dublin 460
Council Bluffs 406
Milan 398
Chandler 389
Toronto 373
Ho Chi Minh City 333
Hanoi 313
New York 313
Houston 299
Wilmington 266
Santa Clara 254
Los Angeles 242
Dallas 223
Beijing 211
Chicago 206
Jacksonville 200
Seattle 187
Cambridge 184
Princeton 184
The Dalles 151
Hefei 137
Rome 118
Dearborn 112
Buffalo 101
Lauterbourg 101
Lawrence 88
São Paulo 82
Moscow 81
Altamura 75
Boardman 70
Seoul 68
Vienna 68
San Diego 59
Munich 56
Helsinki 53
Shanghai 52
Nanjing 49
Jakarta 46
Phoenix 46
Haiphong 43
London 42
Orem 42
Montreal 41
Da Nang 40
Turin 39
Warsaw 39
Denver 35
Atlanta 34
Brooklyn 33
Guangzhou 33
Lachine 31
Nuremberg 31
Rio de Janeiro 31
Columbus 30
Naples 30
Tokyo 30
Salt Lake City 29
Turku 29
Baghdad 26
Philadelphia 26
Chennai 23
Andover 22
Bogotá 22
Lissone 22
North Bergen 22
Biên Hòa 21
Brasília 21
Figino 21
Thái Nguyên 21
Amsterdam 20
Boston 20
Dhaka 20
Las Vegas 20
Mexico City 20
San José 20
Stockholm 20
Washington 20
Johannesburg 19
Paris 19
Bologna 18
Tampa 18
Falls Church 17
Florence 17
Hải Dương 17
Lappeenranta 17
Miami 17
Queens 17
Quận Bình Thạnh 17
Tegucigalpa 17
Buenos Aires 16
Can Tho 16
Jeddah 16
Totale 15.397
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 597
Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and/or high-dose methotrexate-induced acute kidney injury 486
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 486
Acute myeloid leukaemia niche regulates response to L-asparaginase 479
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis 450
ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells 401
A novel EP300 mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency 392
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 385
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 369
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases 358
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 350
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 349
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 342
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study 332
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 332
Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child 330
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 324
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 323
Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma 320
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 319
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 317
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 315
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 303
Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience 300
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 299
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 288
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 282
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 279
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica 270
First-Line Postremission Blinatumomab as Successful Toxicity-Sparing Strategy in a Boy with Cystic Fibrosis and Acute Lymphoblastic Leukemia 261
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 260
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 259
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 259
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica 259
Outcome of very late relapse in children with acute lymphoblastic leukemia 253
Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature 253
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 253
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 252
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy 250
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 250
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic target 247
Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia 247
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 246
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 240
Williams syndrome and mature B-Leukemia: A random association? 240
Role of DNA index in childhood acute lymphoblastic leukemia treated with BFM based therapy: Long term results of the AIEOP-ALL 95 220
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia 219
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers 217
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study 213
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia 208
Legionellosis in paediatrics [Legionellosi in pediatria] 208
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica 207
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 207
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment 206
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia 206
Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study 205
PEDIATRIC PAX5-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IS A HIGH-RISK MOLECULAR SUBGROUP OF B-ALL WITH A POOR MRD-DEPENDENT PROGNOSTIC PROFILE 203
Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) 203
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups 199
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies 198
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II 197
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 193
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol 191
Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study 191
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL 191
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial 186
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 186
MTHFR 677C-->T mutation and neural-tube defects 183
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia 183
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach 178
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 177
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction 177
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 175
A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1 174
Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO 173
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war 167
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product 167
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 162
NUP214–ABL1 fusion in childhood T-ALL 161
Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy 160
Molecularly Targeted Small Molecule Inhibitor Therapy for Pediatric Acute Lymphoblastic Leukemia: A Comprehensive Review of Clinical Trials 157
Collaborative efforts driving progress in pediatric acute myeloid leukemia 156
Biological therapies in monogenic autoinflammatory diseases: Long-term efficacy and safety 155
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias 153
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia 149
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza 149
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial 144
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 138
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety 138
Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia 137
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation 135
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring 134
Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project 134
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia 132
Emapalumab in children with primary hemophagocytic lymphohistiocytosis 131
Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial 130
Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Working Group on preparedness of clinical trials about paediatric medicines process 128
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement 127
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data 127
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study 125
Totale 23.876
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.103
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.103
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022858 0 0 0 0 141 135 53 67 106 81 71 204
2022/20231.712 247 528 95 149 112 278 18 82 117 16 44 26
2023/20241.355 83 33 58 69 168 353 275 32 117 22 18 127
2024/20253.880 182 509 210 183 307 94 171 82 462 567 374 739
2025/20269.857 1.099 590 696 959 972 842 1.475 450 635 769 647 723
2026/20273.364 363 459 958 1.472 112 0 0 0 0 0 0 0
Totale 25.892